BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bruce IN, Golam S, Steenkamp J, Wang P, Worthington E, Desta B, Psachoulia K, Erhardt W, Tummala R. Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. J Comp Eff Res 2022. [PMID: 35546484 DOI: 10.2217/cer-2022-0040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Ballew N, Mian A, Levy RA, Bradley M. Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. J Comp Eff Res 2023;12:e220106. [PMID: 36515082 DOI: 10.2217/cer-2022-0106] [Reference Citation Analysis]
2 Bruce IN, Golam S, Steenkamp J, Wang P, Worthington E, Desta B, Psachoulia K, Erhardt W, Tummala R. Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. J Comp Eff Res 2023;12:e220192. [PMID: 36515083 DOI: 10.2217/cer-2022-0192] [Reference Citation Analysis]
3 Steiger S, Ehreiser L, Anders J, Anders H. Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials. Front Immunol 2022;13:999704. [DOI: 10.3389/fimmu.2022.999704] [Reference Citation Analysis]
4 Kirou KA, Dall`era M, Aranow C, Anders H. Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. Front Immunol 2022;13:980079. [DOI: 10.3389/fimmu.2022.980079] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Oh S, Payne AS. Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept. Immune Netw 2022;22. [DOI: 10.4110/in.2022.22.e37] [Reference Citation Analysis]